Sandrine Niyongere, MD

Education

• Bachelor of Science, Biology with minor chemistry, University of Alabama at Birmingham
• Doctor of Medicine, University of Alabama School of Medicine

Post-Graduate Education and Training

• Residency, Internal Medicine, Northwestern University Feinberg School of Medicine
• Fellowship, Hematology and Medical Oncology, H. Lee Moffitt Cancer Center/University of South Florid

Board Certified

• Internal Medicine
• Medical Oncology
• Hematology

Dr. Niyongere joined the University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center as an Assistant Professor in 2018.  Her clinical focus is in adult leukemias, chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome, myeloproliferative neoplasms, and bone marrow failure disorders.  Her research interest is focused on understanding oncogenic signaling pathways involved in the development of chronic myelomonocytic leukemia and acute myeloid leukemia with the goal of finding new therapeutic targets in the laboratory. She has been involved in several clinical trials and has served as the local principal investigator for several industry-sponsored clinical trials. In addition to clinical and research activities, Dr. Niyongere regularly serves as an attending physician on the inpatient leukemia service training fellows, internal medicine residents, and medical students.

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia

1. Sanchez-Petitto G, Goloubeva O, Childress J, Iqbal T, Masur J, An M, Muhammad S, Lawson J, Li G, Barr B, Emadi A, Duong VH, Hardy NM, Rapoport AP, Baer MR, Niyongere S, Yared J. Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation. Acta Haematol. 2024 Aug 27. 
2. Sanchez-Petitto G, Goloubeva OG, Masur J, Childress J, Iqbal T, An M, Muhammad S, Lawson J, Li G, Barr B, Emadi A, Law JY, Lee ST, Duong VH, Baer MR, Niyongere S. Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease. Leuk Res. 2024 Mar;138:107456.
3. Mustafa Ali MK, Williams MT, Corley EM, AlKaabba F, Niyongere S. Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2023 May;64(5):962-971
4. Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322
5. Mustafa Ali MK, Corley EM, Alharthy H, Kline KAF, Law JY, Lee ST, Niyongere S, Duong VH, Emadi A, Baer MR. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study. Front Oncol. 2022 Mar 31;12:858202.
6. Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia. 2020 Nov 16. 
7. Niyongere S,  Sanchez-Petitto G, Masur J, Baer MR, Duong VH, Emadi A. Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals (Basel). 2020 Jun 16;13(6):124.     
8. Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. 2019 Mar 20.  
9. Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Heterogenous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2018 Jul 19.
10. Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique. Blood. 2017 Jun 2.